Pfizer makes moves to acquire Seagen in potential $30B+ deal
Pfizer is in talks to acquire cancer drugmaker Seagen in a deal that could be worth more than $30 billion, after acquisition talks between Merck …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.